Immunomodulatory effects of intravenous immunoglobulins (IVIGs) in HIV-1 disease: A systematic review
Abstract
Intravenous immunoglobulins (IVIGs) are generally used as replacement therapy for humoral immunodeficiencies. In consideration of their immune-modulating properties, they are also employed as “immune-modulating/ anti-inflammatory” treatment in different clinical conditions. In HIV-1 infection, an increased incidence of autoimmune and auto-inflammatory manifestations has been described, probably as a consequence of the chronic immune activation associated with the disease. The initial use in the treatment of bacterial infections in children with HIV/AIDS has been replaced by the treatment, in combination with antiretroviral therapy, of these autoimmune/inflammatory conditions. We review the results obtained with IVIGs therapy in these HIV-1-associated clinical manifestations.
Authors
Pastori D, Esposito A, Mezzaroma I.
Year
2011
Topics
- Population(s)
- Children or Youth (less than 18 years old)
- General HIV+ population
- Other